# CJC-1295 FAQ: Safety, FDA Status, DAC, and Detection Questions > CJC-1295 FAQ: is it FDA approved, is it a steroid, is it safe, what is DAC, does it affect testosterone, and how is it detected. Direct, cited answers from the published literature. The questions people actually ask about CJC-1295 — safety, FDA and WADA status, the DAC distinction, testosterone, and detection — answered directly and cited where there are numbers. ## Frequently asked questions about CJC-1295 These answers summarize CJC-1295 from the published literature. They describe what studies measured and where the record stops; none is medical advice, and none endorses use. ### What is CJC-1295? CJC-1295 is a synthetic long-acting analog of growth-hormone-releasing hormone built on hGRF(1-29) with four protease-resistant substitutions; the DAC variant adds covalent serum-albumin conjugation for a multi-day half-life [7]. The no-DAC form, Modified GRF (1-29), keeps the substitutions but is short-acting [7]. ### What does CJC-1295 do? In studies it binds the GHRH receptor on pituitary somatotrophs and stimulates growth-hormone release, raising hepatic IGF-1; human PK studies showed sustained GH and IGF-1 elevation [1][7][8]. In healthy men a single 60 or 90 µg/kg dose raised basal GH roughly 7.5-fold one week later, and GH pulsatility was preserved despite the sustained stimulation [8]. ### Is CJC-1295 safe? CJC-1295 is unapproved, and human safety data are limited to early PK studies; theoretical concerns include fluid retention, IGF-1/cancer epidemiology, and immunogenicity flagged by the 2024 FDA PCAC [11]. This is not a safety endorsement — the long-term profile in healthy adults has not been studied. ### Are CJC-1295 peptides safe? Human safety evidence is thin and short-term; sustained GH/IGF-1 elevation raises theoretical concerns, and the compound is unapproved [11]. The controlled human record is a handful of early pharmacokinetic studies [1][8], with no large or long-term safety trial behind it. This summarizes the literature, not a safety claim. ### Is CJC-1295 FDA approved? No. CJC-1295 is not approved for human use by the FDA or any major regulator; it is handled as a research chemical and was not recommended for the 503A compounding bulks list at the 2024 FDA PCAC [11]. The [FDA approval status](/faq) and the WADA prohibition together define its regulatory standing. ### Is CJC-1295 a steroid? No. CJC-1295 is a peptide GHRH analog that acts on the GHRH receptor to stimulate the body's own growth-hormone release; it is not an anabolic steroid [7]. It works upstream, on the pituitary, rather than as a hormone replacement. ### What is CJC-1295 DAC? "DAC" is the Drug Affinity Complex modification that conjugates the peptide to albumin; CJC-1295 DAC is the long-acting form, distinct from the short-acting no-DAC Modified GRF (1-29) [7]. Its estimated half-life is 5.8 to 8.1 days, and IGF-1 elevation persisted up to 28 days after multiple doses in healthy adults [1]. ### What is CJC-1295 with DAC? CJC-1295 with DAC carries a maleimidopropionyl linker that covalently binds circulating serum albumin, extending plasma residence to a multi-day half-life; the no-DAC form lacks this and is short-acting [7]. That albumin tether is the single feature separating the long-acting and short-acting forms of the same tetrasubstituted sequence. ### How much CJC-1295 should I take? Published human PK studies used single subcutaneous doses of 30, 60, or 90 µg/kg in healthy adults [1][8]; these are research doses, not a human-use recommendation, and there is no approved dosing. No regulator has defined a safe or effective dose, because the compound is unapproved for any indication. ### How much CJC-1295 DAC should I take? The DAC variant's multi-day half-life of 5.8 to 8.1 days [1] underlies the spaced schedules cited in research, but community fixed-dose protocols are not derived from controlled human trials. The only human dosing on record is the weight-based single-dose PK work, not a maintenance regimen. ### How much CJC-1295 / ipamorelin should I take? The GHRH-analog-plus-secretagogue pairing rests on a two-receptor synergy rationale (GHRH plus GHRP) [15], but specific combined human dosing is not established in controlled trials. No published study defines a combined dose or schedule for this pairing in healthy adults. ### How to reconstitute CJC-1295? In research handling, the lyophilized peptide is reconstituted with bacteriostatic water and refrigerated; oral bioavailability is negligible, so subcutaneous injection is the route studied [1][7]. This describes laboratory handling of a research material, not a preparation instruction for use. ### Where to inject CJC-1295? Subcutaneous injection is the primary route in the published literature [1][8]; this is a description of research methods, not administration guidance. Intravenous administration appears only in the early native GRF(1-29) pharmacokinetic work [6], and the peptide is not orally active. ### What is CJC-1295 ipamorelin? It refers to combining the GHRH analog CJC-1295 with ipamorelin, a selective GH secretagogue, to engage two GH-release pathways at once [15]. The two act on different receptors, so stimulating both can amplify the pituitary GH pulse beyond what either does alone. ### Does CJC-1295 and ipamorelin work? Mechanistically, GHRH analogs and GHRPs act through distinct receptors and co-administration can produce supra-additive GH release [15]. Controlled efficacy data for this specific pairing in healthy adults are limited; the synergy is well-grounded at the receptor level but not characterized in a dedicated combined human trial. ### What are the side effects of CJC-1295? Reported and theoretical concerns include fluid retention and edema (GH-driven sodium retention), effects on insulin sensitivity, IGF-1/cancer-risk epidemiology, and immunogenicity noted by the 2024 FDA PCAC [11]. Human safety data are short-term, so the long-term profile in healthy adults is uncharacterized. ### What to expect when taking CJC-1295? Human PK studies described dose-dependent multi-day elevation of GH and IGF-1 with preserved pulsatility [1][8]. That is a description of measured endpoints in a small number of volunteers, not an expectation of personal results, and it does not extend to efficacy or long-term safety. ### Does CJC affect testosterone? CJC-1295 acts on the GH/IGF-1 axis, not the gonadal axis; the published literature does not establish a direct testosterone effect [7]. Its target is the GHRH receptor on pituitary somatotrophs, a different signaling route from the hypothalamic-pituitary-gonadal axis that governs testosterone, and no study reports a testosterone change. ### Does CJC-1295 lower testosterone? There is no established mechanism or published evidence that CJC-1295 lowers testosterone; it targets the GHRH receptor and the GH/IGF-1 axis [7]. Claims of a testosterone-lowering effect are not supported in the literature, which has measured GH and IGF-1 endpoints rather than gonadal hormones [1][8]. ### How is CJC-1295 detected in anti-doping testing? Anti-doping laboratories identify CJC-1295 with high-resolution LC-MS/MS, first used to identify it in a seized GHRH preparation [2], and screens including immuno-PCR and immunoaffinity-LC-MS have been developed for GHRH analogs in human and equine matrices [3][4][13]. Screen broadly, then confirm the exact sequence. ### What is CJC-1295's WADA status for tested athletes? The WADA Prohibited List bans growth-hormone-releasing factors and their analogs, CJC-1295 included, under Section S2 at all times, in and out of competition [14]. There is no permitted window for a tested athlete, and bodies such as the NCAA enforce parallel prohibitions. ### Are peptides safer than TRT? This comparison is not answerable from CJC-1295's evidence base: CJC-1295 is unapproved with limited human safety data, whereas approved analogs like tesamorelin have RCT-level data [12]. No safety ranking is implied, and the two are not directly comparable on the published record. ## Why these answers stay cautious A recurring theme runs through every answer above: the question is often broader than the evidence. People ask whether CJC-1295 is safe, whether it works, or how it compares to other interventions — reasonable questions that the published record simply cannot answer at that scope. The human literature is a handful of early pharmacokinetic studies in healthy volunteers [1][8], a foundational animal program [7][9], and a discontinued Phase 2 trial. That is enough to describe how the molecule behaves over days; it is not enough to make safety or efficacy claims, and we do not. So the answers here describe what was measured and name where the record stops. CJC-1295 is unapproved, prohibited in tested sport under WADA Section S2 [14], and was not recommended for the 503A compounding bulks list at the 2024 FDA PCAC [11]. The DAC and no-DAC forms differ by orders of magnitude in duration and should never be treated as one thing. Where a popular claim outruns the data — anti-aging, muscle-building, a clean safety profile — the honest answer is that the peer-reviewed evidence in healthy adults is thin and short-term. That caution is not evasion; it is the shape of the literature. --- The CJC-1295 record drawn out on a teaching whiteboard — each finding wired to its study by an arrow, the DAC-versus-no-DAC fork kept apart, and the unapproved status posted in plain marker; no clinic behind the board and nothing here dispensed or sold.